Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Discrepancies in...

    Discrepancies in documents submitted by Meril Life Science for exempting MeRes100 from price cap; NPPA stalls decision

    Farhat NasimWritten by Farhat Nasim Published On 2019-12-18T14:55:05+05:30  |  Updated On 18 Dec 2019 2:55 PM IST

    New Delhi: In a blow to Gujarat-based stent maker, Meril Life Sciences, the apex price regulator, National Pharmaceutical Pricing Authority (NPPA) has decided hold back the decision to exempt the firm's flagship Sirolimus-Eluting BioResorbable vascular scaffold system (MeRes100) from price cap exemption under paragraph 32 of the Drug Price Control Order (DPCO), 2013.


    The decision came following the discrepancies found by NPPA in the submissions made by the firm seeking exemption from price cap for MeRe100, a drug-coated product that naturally dissolves over a period of time, after it received the drug regulator’s approval in 2017 for the stent.


    The firm had moved an application with NPPA for the same. The company has been striving to clear the decks for MeRes100 since long. However, last month, with an industry association raising health and safety concerns, the application got stuck.


    Also Read: With questions about the safety of Meril’s Made in India BVS stent, NPPA defers its appeal for price exemption


    A month after this, the application was once again deliberated during a meeting held on December 9, 2019, under the Chairmanship of Shubhra Singh, Chairman, NPPA. The meeting was attended by other members including A K Pradhan, Deputy Drug Controller, Department of Health and Family Welfare, Dr V G Somani, Drug Controller General of India(DCGI).


    NPPA examined the matter in detail. It was noted by the authority that Meril has applied for price exemption under Para 32(ii) of DPCO 2013 with respect to its product cardiac stent named “MeRes-100 – Sirolimus-Eluting Bioresorbable Vascular Scaffold System” in which Patent Registration No. 296768 dated 14.05.2018 was mentioned.


    However, from the documents of the Patent office submitted by the company, it was observed that the patent is for “Annealing process for a bioabsorbable stent”. NPPA further noted that the DCGI license submitted by Meril Life Science is for “Sirolimus-Eluting bioresorbable Vascular Scaffold system (cardiac stent).


    Accordingly, NPPA directed the company to furnish an explanation for submitting discrepant documents.


    "The company may be asked to explain the reasons for submission of these discrepant documents for seeking price exemption under Para 32 of DPCO 2013, " NPPA noted.

    Biodegradable stentsBVScoronary stentDCGIDrug Controller General of IndiaGovernment of Indiaindian govtmedical device newsMeRes100MerilMeril Life Sciencesmeril newsNational Pharmaceutical Pricing AuthorityNPPAprice capStents

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok